LivaNova PLC Dossier
Qualitative Analysis
Business overview
LivaNova PLC is a global medical technology company specializing in cardiopulmonary and neuromodulation solutions. Domiciled in the United Kingdom and listed on Nasdaq (LIVN), the company operates primarily through two core business units. The Cardiopulmonary segment is a market leader in heart-lung machines, oxygenators, and autotransfusion systems, highlighted by the rollout of its next-generation Essenz Perfusion System. The Neuromodulation segment focuses on implantable devices for drug-resistant epilepsy and difficult-to-treat depression. LivaNova is also advancing its pipeline in obstructive sleep apnea (OSA) with its aura6000 system. Geographically, the United States is its largest market, followed by Europe and the Rest of World.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Scaling the aura6000 proximal hypoglossal nerve stimulation (p-HGNS) technology following positive clinical data from the OSPREY trial and FDA PMA approval.
Expected impact: Entry into a multi-billion dollar underpenetrated market, projected to generate substantial high-margin revenue streams.
Capitalizing on the market opportunity for the Essenz Perfusion System through an upgrade replacement cycle, consumables market-share gains, and next-generation oxygenator development.
Expected impact: Expected to generate mid-to-high single-digit revenue CAGR and adjusted operating margin expansion of more than 300 basis points in the Cardiopulmonary segment.
Optimizing the capital structure and footprint through strategic debt repayments and operational cost discipline under the 'LivaNova Excellence' framework.
Expected impact: Reduces interest expenses, improves financial flexibility, and supports adjusted operating margin expansion toward the 20.0%-21.0% target for 2026.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired remaining stake to obtain full ownership of ALung's Hemolung extracorporeal carbon dioxide removal (ECCO2R) system, complementing LivaNova's cardiopulmonary product portfolio.
Financial impact: Expanded the advanced respiratory support offerings within the Cardiopulmonary segment.
Strategic Partnerships
High. Collaborating on coverage and reimbursement pathways, particularly for VNS Therapy in Difficult-to-Treat Depression (DTD) through the RECOVER study and the updated 2026 outpatient reimbursement rates for Epilepsy.
Terms: Non-monetary strategic alignment; directly impacts provider reimbursement levels and product adoption.